AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2,-Reference-Cited by-同舟云学术

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2,

Published:2011-12-19 Issue:3 Volume:55 Page:833-845
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Ho Coral,Wang Chunmei,Mattu Sandra,Destefanis Giulia,Ladu Sara,Delogu Salvatore,Armbruster Julia,Fan Lingling,Lee Susie A.,Jiang Lijie,Dombrowski Frank,Evert Matthias,Chen Xin,Calvisi Diego F.

Publisher

Wiley

Subject

Hepatology

Reference31 articles.

1. Focus on hepatocellular carcinoma;Bruix;Cancer Cell,2004

2. Targeted therapy for hepatocellular carcinoma;Spangenberg;Nat Rev Gastroenterol Hepatol,2009

3. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC;Calvisi;Gastroenterology,2006

4. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer;Calvisi;J Hepatol,2011

5. Pivotal role of mTOR signaling in hepatocellular carcinoma;Villanueva;Gastroenterology,2008

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Context-Dependent Distinct Roles of SOX9 in Combined Hepatocellular Carcinoma–Cholangiocarcinoma;Cells;2024-08-29

2. CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells;Journal of Advanced Research;2024-08

3. Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges;Biomedicines;2024-07-22

4. Aberrant differentiation and proliferation of hepatocytes in chronic liver injury and liver tumors;Pathology International;2024-06-05

5. Tumor Microenvironment‐Responsive Nanocapsule Delivery CRISPR/Cas9 to Reprogram the Immunosuppressive Microenvironment in Hepatoma Carcinoma;Advanced Science;2024-05-05